McKesson Corporation (MCK)

Not Just a ‘Drug Wholesaler’ — McKesson Is Reinventing Itself

If you know McKesson (MCK) as a company that simply moves pharmaceuticals from manufacturers to pharmacies and hospitals on razor-thin margins, that story is out of date. Since 2025, McKesson has been executing a major strategic pivot: from a high-volume, low-margin pure pharmaceutical distributor into a more diversified, higher-margin specialty healthcare platform centered on Oncology & Multispecialty — while simultaneously shedding its slowest-growth segment via a corporate spin-off.

Revenue by Segment (FY2026)

North American Pharmaceutical remains the revenue engine — but it is also, by a wide margin, the thinnest-margin segment in the portfolio. Oncology & Multispecialty is far smaller in absolute revenue, but it is the piece being aggressively built out through M&A because its margin profile and growth rate are structurally more attractive.

Building Out Oncology Through M&A

In just two months (April–June 2025), McKesson closed two large deals within the Oncology & Multispecialty segment:

• PRISM Vision Holdings — an 80% controlling stake for $875 million cash (April 2025), focused on ophthalmology/retina administrative services.
• Core Ventures (with Florida Cancer Specialists & Research Institute, FCS) — a 70% controlling stake for $2.5 billion cash (June 2025), a community oncology revitalization platform.

Notice the pattern across both deals: McKesson is buying majority stakes, not 100%. The original physician groups retain minority ownership (20% for PRISM Vision, 30% for FCS). This is a deliberate alignment structure — the specialist physicians actually running day-to-day operations keep economic skin in the game, lowering the risk they walk away and rebuild elsewhere post-acquisition.

Medical-Surgical Solutions Spin-off (‘NewCo’)

Announced in May 2025, McKesson plans to separate its Medical-Surgical Solutions segment (non-pharmaceutical medical/surgical supplies) into a standalone public company, currently referred to as ‘NewCo’. The original 12–18 month timeline (implying mid-2026) has slipped to the second half of calendar 2027 — a point worth flagging (see Catalysts/Risks section). In April 2026, Apollo Global Management invested $1.25 billion for a 13% minority stake in NewCo via convertible preferred equity, lending institutional credibility and part-funding the separation process.

Shariah Compliance Status

✅ Per Zoya’s screening, McKesson Corporation (MCK) is confirmed SHARIAH-COMPLIANT. This means its core business model — pharmaceutical distribution, oncology services, and health technology — passes the standard Shariah financial-ratio and business-activity screens Zoya applies.

This section is being refreshed with the latest figures. Please check back soon.

This section is being refreshed with the latest figures. Please check back soon.